Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, parallel group, randomized, double-blind, double-dummy, placebo and active-controlled multicenter trial to investigate the efficacy, tolerability and safety of fesoterodine sustained release in subjects with overactive bladder syndrome

Next Previous
X
Search
Trial Profile

A phase 3, parallel group, randomized, double-blind, double-dummy, placebo and active-controlled multicenter trial to investigate the efficacy, tolerability and safety of fesoterodine sustained release in subjects with overactive bladder syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fesoterodine (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer; UCB

    • Most Recent Events

    • 01 Aug 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004018).
    • 01 Aug 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004018).
    • 09 Apr 2008 Pfizer has replaced UCB Pharma as a trial sponsor, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top